Patients reaching Psoriasis Area Severity Index (PASI) 75 (≥ 75% improvement in the PASI) at the end of the core phase (24 weeks) were eligible to enter the extension phase. In the core phase, all patients received subcutaneous secukinumab 300 mg weekly for the first 5 weeks followed by 300 mg every 4 weeks (q4w). Patients entering the extension phase self-administered 300 mg q4w until week 72. Herein, we present the efficacy and safety results from the extension phase of the SUPREME study. The patients completed the study, after marketing authorization was received, at any time after the first visit of the extension phase (week 36).

Secukinumab shows high efficacy irrespective of HLA-Cw6 status in patients with moderate-to-severe plaque-type psoriasis: results from extension phase of the SUPREME study.

Girolomoni, G;
2019-01-01

Abstract

Patients reaching Psoriasis Area Severity Index (PASI) 75 (≥ 75% improvement in the PASI) at the end of the core phase (24 weeks) were eligible to enter the extension phase. In the core phase, all patients received subcutaneous secukinumab 300 mg weekly for the first 5 weeks followed by 300 mg every 4 weeks (q4w). Patients entering the extension phase self-administered 300 mg q4w until week 72. Herein, we present the efficacy and safety results from the extension phase of the SUPREME study. The patients completed the study, after marketing authorization was received, at any time after the first visit of the extension phase (week 36).
secukinumab
HLA-Cw6
moderate-to-severe plaque-type psoriasis
File in questo prodotto:
File Dimensione Formato  
Secukinumab shows high efficacy irrespective of HLA-Cw6 status in patients with moderate-to-severe plaque-type pso BJD 2019.pdf

non disponibili

Tipologia: Documento in Post-print
Licenza: Accesso ristretto
Dimensione 252.19 kB
Formato Adobe PDF
252.19 kB Adobe PDF   Visualizza/Apri   Richiedi una copia

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11562/998282
Citazioni
  • ???jsp.display-item.citation.pmc??? 3
  • Scopus 13
  • ???jsp.display-item.citation.isi??? ND
social impact